The stock of Rallybio Corp (RLYB) has gone down by -5.33% for the week, with a -19.36% drop in the past month and a -37.72% drop in the past quarter. The volatility ratio for the week is 13.85%, and the volatility levels for the past 30 days are 10.58% for RLYB. The simple moving average for the last 20 days is -12.17% for RLYB stock, with a simple moving average of -43.12% for the last 200 days.
Is It Worth Investing in Rallybio Corp (NASDAQ: RLYB) Right Now?
Moreover, the 36-month beta value for RLYB is -1.38. Analysts have varying opinions on the stock, with 3 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for RLYB is 20.47M and currently, short sellers hold a 1.65% of that float. On March 25, 2025, RLYB’s average trading volume was 65.48K shares.
RLYB) stock’s latest price update
The stock price of Rallybio Corp (NASDAQ: RLYB) has plunged by -9.25 when compared to previous closing price of 0.67, but the company has seen a -5.33% decline in its stock price over the last five trading sessions. businesswire.com reported 2025-02-11 that NEW HAVEN, Conn.–(BUSINESS WIRE)–Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that the first participant has been dosed in the Phase 2 trial investigating RLYB212 in pregnant women at higher risk for HPA-1a alloimmunization and fetal and neonatal alloimmune thrombocytopenia (FNAIT). Pharmacokinetic (PK) and safety data from the second trimes.
Analysts’ Opinion of RLYB
Jefferies, on the other hand, stated in their research note that they expect to see RLYB reach a price target of $1.50, previously predicting the price at $7. The rating they have provided for RLYB stocks is “Hold” according to the report published on February 07th, 2024.
H.C. Wainwright gave a rating of “Buy” to RLYB, setting the target price at $18 in the report published on April 17th of the previous year.
RLYB Trading at -22.17% from the 50-Day Moving Average
After a stumble in the market that brought RLYB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -82.43% of loss for the given period.
Volatility was left at 10.58%, however, over the last 30 days, the volatility rate increased by 13.85%, as shares sank -18.62% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -38.96% lower at present.
During the last 5 trading sessions, RLYB fell by -5.33%, which changed the moving average for the period of 200-days by -60.52% in comparison to the 20-day moving average, which settled at $0.6922. In addition, Rallybio Corp saw -36.67% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for RLYB
Current profitability levels for the company are sitting at:
- -95.12 for the present operating margin
- 0.89 for the gross margin
The net margin for Rallybio Corp stands at -90.84. The total capital return value is set at -0.98. Equity return is now at value -68.85, with -62.89 for asset returns.
Based on Rallybio Corp (RLYB), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -320.01.
Currently, EBITDA for the company is -60.5 million with net debt to EBITDA at 0.23. When we switch over and look at the enterprise to sales, we see a ratio of 18.16. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.87.
Conclusion
To wrap up, the performance of Rallybio Corp (RLYB) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
